Sanofi

Sanofi added its "bold" decision to go without earlier-stage clinical COPD trials had shaved years off the development time

The drugmaker is offering voluntary retirement scheme (VRS) to all its employees at two sites near Hyderabad

With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon

Drug firm Sanofi India on Thursday reported a net profit of Rs 131 crore for the third quarter ended September 2022. The company had posted a net profit of Rs 530 crore in the July-September quarter of last year, the company said in a regulatory filing. The drug firm follows a January-December financial year. Revenue from operations stood at Rs 692 crore in the period under review. The same stood at Rs 754 crore in the corresponding period previous year. The company said the results of the September quarter were not comparable with the same quarter last year as it had transferred its nutraceuticals business to Universal Nutriscience, enabling a gain of Rs 489 crore.

Sanofi fell 13% on Thursday, taking its 2-day decline to 20%; GSK slid 6.9%

The companies point to the risk of new variants and waning immunity that could lead to an increase in demand for additional booster shots in some populations.

Sanofi-GSK's shot relies on a conventional protein-based approach, compared with the newer mRNA technology used in established Covid-19 vaccines from Pfizer-BioNTech and Moderna

Will also acquire other legacy associated brands such as Sofradex (antibacterial cream), Sofracort (eye and ear drops), Soframycin-Tulle (cream) for India and Sri Lanka markets

French drugmaker Sanofi said Tuesday it was shelving plans for a Covid-19 vaccine based on messenger RNA despite positive results from early stage testing

The pharmaceutical giant, which has lagged rivals in deploying technology behind some of the world's top-selling Covid shots, made the decision despite positive results in phase one and two trials

German biotech firm CureVac earlier this month also acknowledged rivals' dominance

Sanofi has lagged behind upstarts BioNTech SE and Moderna Inc. in the pandemic as they raced ahead with mRNA shots that have now been injected into arms more than a billion times

Semglee may now be substituted for Sanofi's Lantus by a pharmacist in the US

India part of 35,000 volunteer global efficacy trial

The mRNA technology has proven both effective and safe so far in the vaccine response to COVID-19, including in response to the virus' variants.

Pharma giant is talking with the UK and other governments about building facilities to bring vaccine development onshore before the next crisis.

Volunteers showed a similar antibody response to people who have recovered from the coronavirus, the companies said in a statement Monday.

Drug firm Sanofi India on Tuesday reported a net profit of Rs 145.9 crore for the March ended quarter.

The price paid by different governments for a vaccine dose - including for the same vaccine - varies across countries, Unicef data shows

Bristol-Myers and Sanofi, which produced Plavix in a partnership, in a joint statement vowed to appeal, saying the decision was "unsupported by the law and at odds with the evidence at trial"